問卷

TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of General Internal Medicine

Division of Family Medicine

更新時間:2023-09-19

徐華穗Hsu, Hua-Shui
  • Co-Principal Investigator
  • Clinical Trial Experience (year) 13 years
  • D8044@mail.cmuh.org.tw

篩選

List

13Cases

2023-09-15 - 2025-10-22

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Not yet recruiting2Sites

Terminated3Sites

2026-03-01 - 2030-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

2026-03-01 - 2030-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

2023-01-30 - 2026-01-26

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-04-01 - 2024-12-03

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2023-06-16 - 2024-05-15

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-11-05 - 2027-02-02

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting5Sites

2022-11-01 - 2027-02-22

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites

2024-01-01 - 2025-12-31

Phase IV

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2023-09-15 - 2025-10-22

Phase III

Completed
Efficacy and safety of semaglutide 2.4 mg once-weekly in adults with overweight and obesity (STEP 12)
  • Condition/Disease

    overweight and obesity

  • Test Drug

    injection

Participate Sites
5Sites

Recruiting5Sites

1 2